Medpace Holdings, Inc.

NasdaqGS:MEDP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

Location

United States

Market Cap

USD 8.93 B

Share Price

USD 310.69

Avg Daily Volume

494,823

Change (1 day)

1.27%

Change (1 year)

-26.78%

Change (YTD)

-6.48%

Medpace Holdings, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 22.32%

Medpace Holdings, Inc. EBT Margin is 22.32% for the Trailing 12 Months (TTM) ending March 31, 2025, a 20.87% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Medpace Holdings, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 18.47%, a -4.92% change year over year.
Medpace Holdings, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 19.42%, a 7.76% change year over year.
Medpace Holdings, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 18.02%, a -4.68% change year over year.
Medpace Holdings, Inc. EBT Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 18.91%, a 23.29% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBT Margin	Operating Income Margin	Gross Profit Margin	EBIT Margin

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	🏥 Health Care
Industries Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.